Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$148.36−1.16 (-0.78%)
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck Fosamax by Year
Fosamax (alendronate, legacy pre-Organon spin-off) — U.S. reported growth YoY (%) (%)
Merck Fosamax: -33.0% in FY2018, down 54.0 pts from a year earlier. No newer figure appears in the documents we track.
Latest, FY2018
-33.0%
Period ended Dec 31, 2018
Change on a year earlier
-54.0 pts
21.0% in FY2017
History
2 years
Since FY2017
Sources
2
Documents cited below
Where the FY2018 figure comes from
“|| Fosamax | 209 | 241 | -13 | 4 | 6 | -33 | 205 | 235 | -13”
Source: Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Reported in Form 8-K Table 3a / 3b Product Sales.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Fosamax (alendronate, legacy pre-Organon spin-off) — U.S. reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2018 | Dec 31, 2018 | -33.0% | -54.0 pts | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| FY2017 | Dec 31, 2017 | 21.0% | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Cite this data
StockData. (2026). Merck Fosamax (%), annual FY2017–FY2018 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-fosamax-us-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.